CN101939335B - 抗软骨退变的抗原结合多肽 - Google Patents

抗软骨退变的抗原结合多肽 Download PDF

Info

Publication number
CN101939335B
CN101939335B CN200980104195.1A CN200980104195A CN101939335B CN 101939335 B CN101939335 B CN 101939335B CN 200980104195 A CN200980104195 A CN 200980104195A CN 101939335 B CN101939335 B CN 101939335B
Authority
CN
China
Prior art keywords
cartilage
esba105
antigen
articular
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980104195.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN101939335A (zh
Inventor
D·厄里什
P·利希特兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delenex Therapeutics AG
Original Assignee
Delenex Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics AG filed Critical Delenex Therapeutics AG
Publication of CN101939335A publication Critical patent/CN101939335A/zh
Application granted granted Critical
Publication of CN101939335B publication Critical patent/CN101939335B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200980104195.1A 2008-02-05 2009-02-05 抗软骨退变的抗原结合多肽 Expired - Fee Related CN101939335B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2631708P 2008-02-05 2008-02-05
US61/026,317 2008-02-05
US8887608P 2008-08-14 2008-08-14
US61/088,876 2008-08-14
PCT/CH2009/000045 WO2009097704A1 (en) 2008-02-05 2009-02-05 Antigen-binding polypeptides against cartilage degeneration

Publications (2)

Publication Number Publication Date
CN101939335A CN101939335A (zh) 2011-01-05
CN101939335B true CN101939335B (zh) 2015-02-11

Family

ID=40568129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980104195.1A Expired - Fee Related CN101939335B (zh) 2008-02-05 2009-02-05 抗软骨退变的抗原结合多肽

Country Status (10)

Country Link
US (1) US20110002927A1 (cg-RX-API-DMAC10.html)
EP (1) EP2240515A1 (cg-RX-API-DMAC10.html)
JP (1) JP2011510667A (cg-RX-API-DMAC10.html)
CN (1) CN101939335B (cg-RX-API-DMAC10.html)
AU (1) AU2009212079B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0907485A2 (cg-RX-API-DMAC10.html)
CA (1) CA2712965A1 (cg-RX-API-DMAC10.html)
IL (1) IL206720A0 (cg-RX-API-DMAC10.html)
RU (1) RU2010136988A (cg-RX-API-DMAC10.html)
WO (1) WO2009097704A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
US10143762B2 (en) 2013-12-13 2018-12-04 Mercury Assel Management Co., Ltd. Articular cartilage imaging composition
EP3452094B1 (en) * 2016-05-06 2021-11-17 The Brigham and Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
CN113825495A (zh) 2018-10-11 2021-12-21 阿利维奥治疗学股份有限公司 用于智能释放的不可注射水凝胶调配物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131013A2 (en) * 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
WO2008006235A2 (en) * 2006-07-10 2008-01-17 Esbatech Ag Scfv antibodies which pass epithelial and/or endothelial layers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131013A2 (en) * 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
WO2008006235A2 (en) * 2006-07-10 2008-01-17 Esbatech Ag Scfv antibodies which pass epithelial and/or endothelial layers

Also Published As

Publication number Publication date
AU2009212079A1 (en) 2009-08-13
IL206720A0 (en) 2010-12-30
RU2010136988A (ru) 2012-03-20
CA2712965A1 (en) 2009-08-13
EP2240515A1 (en) 2010-10-20
US20110002927A1 (en) 2011-01-06
JP2011510667A (ja) 2011-04-07
BRPI0907485A2 (pt) 2015-08-04
WO2009097704A1 (en) 2009-08-13
AU2009212079B2 (en) 2012-08-30
CN101939335A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
Kaushik et al. Review of safety and efficacy of approved systemic psoriasis therapies
Kimmerling et al. Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNFα single-chain Fv antibody (ESBA105) designed for local therapeutic use
KR102249078B1 (ko) 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드
US9304127B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
US10227405B2 (en) Methods of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance by administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment
Wakamatsu et al. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells
AU2012338730B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
JP7341996B2 (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
PT2390267E (pt) Anticorpos estáveis e solúveis que inibem tnf(alfa)
ES2588484T3 (es) Anticuerpo anti-ADAMTS-5, derivados y usos del mismo
AU2009212079B2 (en) Antigen-binding polypeptides against cartilage degeneration
JP2023138982A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法
US20100099642A1 (en) Tgf-beta stimulant and further agent to reduce side effects
Adhyatmika et al. Osteoprotegerin expression in liver is induced by IL13 through TGFβ
Coll Therapeutic targeting of inflammasome signaling by blocking interleukin-1
CN119546340A (zh) 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法
JP2023071904A (ja) カナキヌマブの使用
Jones What's new in osteoarthritis?
Urech et al. Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF-α scFv (ESBA105) designed for local therapeutic use
US20080194527A1 (en) Compositions and combinations 2
NZ624869B2 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150211

Termination date: 20160205